Wire · operational-macro
FDA Approves Hibsago to Treat Certain Chronic HBV Patients
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 October 2026 · Fusion42 review
The FDA has approved Hibsago injection (bepirovirsen, GSK) in combination with existing antivirals to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. This is the first FDA-approved antisense oligonucleotide for HBV, showing a functional cure rate up to 26% in patients with low surface antigen levels, significantly improving on current treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 21 Oct 2026 and 22 Oct 2026.
◆ ◆ The Wire takeaway
You face a new competitor standard for chronic HBV treatment with functional cure now achievable beyond viral suppression. Clinical teams need to adapt fast or risk losing patient relevance as treatment expectations rise.
◆ Coverage
3 sources · first reported 21 Oct 2026 · latest 22 Oct 2026
◆ Related on Wire
◆ Topics